93 related articles for article (PubMed ID: 20194531)
1. Regulation of copper transporter 2 expression by copper and cisplatin in human ovarian carcinoma cells.
Blair BG; Larson CA; Adams PL; Abada PB; Safaei R; Howell SB
Mol Pharmacol; 2010 Jun; 77(6):912-21. PubMed ID: 20194531
[TBL] [Abstract][Full Text] [Related]
2. Copper transporter 2 regulates the cellular accumulation and cytotoxicity of Cisplatin and Carboplatin.
Blair BG; Larson CA; Safaei R; Howell SB
Clin Cancer Res; 2009 Jul; 15(13):4312-21. PubMed ID: 19509135
[TBL] [Abstract][Full Text] [Related]
3. Gene duplication and neo-functionalization in the evolutionary and functional divergence of the metazoan copper transporters Ctr1 and Ctr2.
Logeman BL; Wood LK; Lee J; Thiele DJ
J Biol Chem; 2017 Jul; 292(27):11531-11546. PubMed ID: 28507097
[TBL] [Abstract][Full Text] [Related]
4. Copper Chaperone Atox1 Protected the Cochlea From Cisplatin by Regulating the Copper Transport Family and Cell Cycle.
Chen X; Xiang W; Li L; Xu K
Int J Toxicol; 2024; 43(2):134-145. PubMed ID: 37859596
[TBL] [Abstract][Full Text] [Related]
5. The role of Ctr1 and Ctr2 in mammalian copper homeostasis and platinum-based chemotherapy.
Öhrvik H; Thiele DJ
J Trace Elem Med Biol; 2015; 31():178-82. PubMed ID: 24703712
[TBL] [Abstract][Full Text] [Related]
6. Distinct function of Chlamydomonas CTRA-CTR transporters in Cu assimilation and intracellular mobilization.
Strenkert D; Schmollinger S; Paruthiyil S; Brown BC; Green S; Shafer CM; Salomé P; Nelson H; Blaby-Haas CE; Moseley JL; Merchant SS
Metallomics; 2024 Mar; 16(3):. PubMed ID: 38439674
[TBL] [Abstract][Full Text] [Related]
7. Crystal structures of cisplatin bound to a human copper chaperone.
Boal AK; Rosenzweig AC
J Am Chem Soc; 2009 Oct; 131(40):14196-7. PubMed ID: 19807176
[TBL] [Abstract][Full Text] [Related]
8. Theaflavin-3,3'-Digallate Enhances the Inhibitory Effect of Cisplatin by Regulating the Copper Transporter 1 and Glutathione in Human Ovarian Cancer Cells.
Pan H; Kim E; Rankin GO; Rojanasakul Y; Tu Y; Chen YC
Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29301278
[TBL] [Abstract][Full Text] [Related]
9. Distinct function of Chlamydomonas CTRA-CTR transporters in Cu assimilation and intracellular mobilization.
Strenkert D; Schmollinger S; Paruthiyil S; Brown BC; Green S; Shafer CM; Salomé P; Nelson H; Blaby-Haas CE; Moseley JL; Merchant SS
bioRxiv; 2023 Oct; ():. PubMed ID: 37905083
[TBL] [Abstract][Full Text] [Related]
10. Copper coordination states affect the flexibility of copper Metallochaperone Atox1: Insights from molecular dynamics simulations.
Schwartz R; Ruthstein S; Major DT
Protein Sci; 2022 Dec; 31(12):e4464. PubMed ID: 36208051
[TBL] [Abstract][Full Text] [Related]
11. AMPK phosphorylates and stabilises copper transporter 1 to synergise metformin and copper chelator for breast cancer therapy.
Zhang X; Jiang Q; Su Y; Bu L; Sun Z; Wu X; Gao B; Wang L; Lin Y; Xie W; Guo J
Br J Cancer; 2023 Apr; 128(8):1452-1465. PubMed ID: 36807336
[TBL] [Abstract][Full Text] [Related]
12. Interaction of classical platinum agents with the monomeric and dimeric Atox1 proteins: a molecular dynamics simulation study.
Wang X; Li C; Wang Y; Chen G
Int J Mol Sci; 2013 Dec; 15(1):75-99. PubMed ID: 24362578
[TBL] [Abstract][Full Text] [Related]
13. Copper transporter 2 regulates endocytosis and controls tumor growth and sensitivity to cisplatin in vivo.
Blair BG; Larson CA; Adams PL; Abada PB; Pesce CE; Safaei R; Howell SB
Mol Pharmacol; 2011 Jan; 79(1):157-66. PubMed ID: 20930109
[TBL] [Abstract][Full Text] [Related]
14. Ctr2 regulates biogenesis of a cleaved form of mammalian Ctr1 metal transporter lacking the copper- and cisplatin-binding ecto-domain.
Öhrvik H; Nose Y; Wood LK; Kim BE; Gleber SC; Ralle M; Thiele DJ
Proc Natl Acad Sci U S A; 2013 Nov; 110(46):E4279-88. PubMed ID: 24167251
[TBL] [Abstract][Full Text] [Related]
15. Copper transporter 2 regulates intracellular copper and sensitivity to cisplatin.
Huang CP; Fofana M; Chan J; Chang CJ; Howell SB
Metallomics; 2014 Mar; 6(3):654-61. PubMed ID: 24522273
[TBL] [Abstract][Full Text] [Related]
16. Association of copper transporter expression with platinum resistance in epithelial ovarian cancer.
Yoshida H; Teramae M; Yamauchi M; Fukuda T; Yasui T; Sumi T; Honda K; Ishiko O
Anticancer Res; 2013 Apr; 33(4):1409-14. PubMed ID: 23564780
[TBL] [Abstract][Full Text] [Related]
17. Deciphering the Molecular Mechanisms behind Drug Resistance in Ovarian Cancer to Unlock Efficient Treatment Options.
Nunes M; Bartosch C; Abreu MH; Richardson A; Almeida R; Ricardo S
Cells; 2024 May; 13(9):. PubMed ID: 38727322
[TBL] [Abstract][Full Text] [Related]
18. Novel players in the development of chemoresistance in ovarian cancer: ovarian cancer stem cells, non-coding RNA and nuclear receptors.
Alam S; Giri PK
Cancer Drug Resist; 2024; 7():6. PubMed ID: 38434767
[TBL] [Abstract][Full Text] [Related]
19. A deep tabular data learning model predicting cisplatin sensitivity identifies BCL2L1 dependency in cancer.
Nasimian A; Ahmed M; Hedenfalk I; Kazi JU
Comput Struct Biotechnol J; 2023; 21():956-964. PubMed ID: 36733702
[TBL] [Abstract][Full Text] [Related]
20. The copper transporter CTR1 and cisplatin accumulation at the single-cell level by LA-ICP-TOFMS.
Schoeberl A; Gutmann M; Theiner S; Corte-Rodríguez M; Braun G; Vician P; Berger W; Koellensperger G
Front Mol Biosci; 2022; 9():1055356. PubMed ID: 36518851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
